Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14982019 | 0.91 | CYP2E1 (0.42) | CYP2E1CYP3A4NR1I2KMT2A | |
| SCHEMBL14982034 | 0.91 | CYP2E1 (0.42) | CYP2E1CYP3A4NR1I2KMT2A | |
| SCHEMBL1963830 | 0.91 | CYP3A4 (0.50) | CYP2E1CYP3A4NR1I2TSHRCASP1 | |
| SCHEMBL1958427 | 0.91 | CYP2E1 (0.41) | CYP2E1CYP3A4NR1I2TSHRCASP1 | |
| SCHEMBL1958761 | 0.89 | CYP2E1 (0.42) | CYP2E1CYP3A4NR1I2TSHRCASP1 | |
| SCHEMBL324463 | 0.88 | CYP2E1 (0.45) | CYP2E1CYP3A4NR1I2TSHRCASP1 | |
| SCHEMBL1960017 | 0.87 | CYP2E1 (0.46) | CYP2E1CYP3A4NR1I2TSHRCASP1 | |
| SCHEMBL1961762 | 0.86 | NR1I2 (0.40) | CYP2E1CYP3A4NR1I2TSHRCASP1 | |
| SCHEMBL1963307 | 0.85 | CYP2E1 (0.39) | CYP2E1CYP3A4NR1I2TSHRCASP1 | |
| SCHEMBL1958417 | 0.83 | CYP2E1 (0.38) | CYP2E1CYP3A4NR1I2TSHRCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130136719-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130136719-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136719-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | HAVCR2, GTF3C3, ZC3HAV1 | CYP2E1 75/4885CYP3A4 583/4885NR1I2 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.